Cookie Settings
This site uses cookies to store information on your computer, to improve your experience. One of the cookies this site uses is essential for parts of the site to operate and has already been set. You may delete and block all cookies from this site, but parts of the site will not work. To find out more about the cookies this site uses and how to delete them, please see the privacy notice.
skip to main content
Home > Services > Research > Research and Development > Previous Studies > DFEND

DFEND

DFEND

A randomised, double blind, placebo controlled parallel group trial of vitamin D supplementation compared to placebo in people presenting with their First Episode of psychosis (DFEND). This study aims to explore how the addition of vitamin D supplements to standard treatments can help people recover after having their first episode of psychosis. 

Participants of the study will continue to receive their standard treatments for psychosis. Half of the participants will be randomly allocated to receive a vitamin D supplement while the other half will receive a placebo treatment. Treatment will last for 6 months with a short home visit each month for the duration of the study.
To take part you must meet the following criteria:

  • Aged between 18-45 years old

  • Diagnosis of psychosis

  • Willing to refrain from taking multivitamins or non-study Vitamin D supplements including cod liver oil

 

NOTE

You cannot take part in this study if:

  • You have a known intolerance of Vitamin D2 or D3 or known allergy to any the trial medication

  • You are currently taking vitamin D supplements at a dose exceeding 400IU/day

  • You have a known current anaemia, sickle cell anaemia and beta or alpha thalassemia

If you would like to take part or want more information please contact the study lead:

 

Study Contact: Joanne McCarthy

Email:  joanne.mccarthy@nhs.net

Tel: 02380 475943

Other studies

Page Comments